Valeant Pharmaceuticals International IncNYSE:VRXview on Canadian Exchange »
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shire PLC SHPG | 17.3B | 31.1x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Allergan Inc AGN | 30.1B | 27.1x | +17.78% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Perrigo Co PRGO | 11.2B | 26.2x | +41.51% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Actavis Inc ACT | 16.0B | -- | -9.83% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Novo Nordisk A/S NVO | 76.1B | 25.7x | +23.74% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On March 12, 2012, it acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc.
| Headquarters | 2150 St. Elzear Blvd., West Laval MONTREAL, QC, Canada H7L 4A8 |
|---|---|
| Phone | 514-744-6792 |
| Fax | 514-744-6272 |
EXECUTIVE OFFICERS
| Chairman of the Board, Chief Executive Officer | J. Michael Pearson |
|---|---|
| Chief Financial Officer, Executive Vice President, Director | Howard Schiller |
| Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development | Robert Chai-Onn |
| Executive Vice President, Company Group Chairman | Laizer Kornwasser |
| Executive Vice President - Administration, Chief Human Capital Officer | Brian Stolz |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $24.0B | Beta | 0.80 |
|---|---|---|---|
| Revenue (TTM) | $3.8B | EPS | $-0.43 |
| Shares Out. | 303.8M | Book Value | $12.23 |
| Dividend Yield | 0.00% | P/E | -- |
| Annual Dividend Rate | -- | Price/Sales (TTM) | 6.4 |
| Ex-Div Date | 1/1/01 | P/Cash Flow (TTM) | 24.8x |
| Pay Date | 1/1/01 | Operating Margin | 2.50% |
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
